Early Alzheimer's Disease / MK-2214 · Phase 2 Trial

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

ClinicalTrials.gov · August 14, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a planned Phase 2 trial of MK-2214, a tau-targeting agent, versus placebo in early Alzheimer's disease, currently recruiting. No efficacy or safety results are available in this registry record; the study aims to assess change in brain tau burden by PET imaging and tolerability over approximately 23–26 months.

What was studied

Phase 2, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Early Alzheimer's Disease; age from 50 Years; to 85 Years. Intervention: MK-2214. Compared with: Placebo — Placebo Comparator. n = 340. 80 sites across 11 countries.

Key findings

Safety

This is a registry record only; no efficacy, safety, or any outcome results are reported.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is an active Phase 2 interventional trial registration with no posted results; it describes a planned study of a novel tau-targeting agent in early Alzheimer's disease with surrogate neuroimaging endpoints.

Study design

As stated by the source record.

MethodsPrimary outcome measures: Change from Baseline in Tau PET Standardized Uptake Value Ratio (SUVr) (assessed at Baseline, up to approximately 23 months); Number of Participants Who Experience One or More Adverse Events (AEs) (assessed at Up to approximately 26 months); Number of Participants Who Discontinue Study Intervention Due to an AE (assessed at Up to approximately 23 months)

DesignPhase 2, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose

PopulationEarly Alzheimer's Disease; age from 50 Years; to 85 Years

Sample size340

InterventionMK-2214

ComparatorPlacebo — Placebo Comparator

Setting80 sites across 11 countries

Reported figures

Quoted from the source exactly as published.

Planned enrollment340

PhasePhase 2

Primary outcome measure 1Change from Baseline in Tau PET SUVr, Baseline up to approximately 23 months

Primary outcome measure 2Number of Participants Who Experience One or More Adverse Events, up to approximately 26 months

Primary outcome measure 3Number of Participants Who Discontinue Study Intervention Due to an AE, up to approximately 23 months

Caveats

This is a registry record only; no efficacy, safety, or any outcome results are reported.
Primary endpoint is a surrogate neuroimaging biomarker (tau PET SUVr), not a clinical cognitive or functional outcome.
Study is actively recruiting; results are not yet available.
Detailed methodology (randomization, blinding, inclusion/exclusion criteria beyond diagnosis) not provided in this registry extract.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Phase 2 interventional trial with placebo comparator; design appropriate for early efficacy signal.

Directness

limited

Primary endpoint is tau PET SUVr, a surrogate; clinical cognitive or functional outcomes not listed.

Consistency

insufficient

No results reported; consistency cannot be assessed from registry record alone.

Risk of bias

insufficient

Study is ongoing; recruitment, blinding status, and allocation concealment not detailed in this registry extract.

Sample adequacy

moderate

Planned enrollment 340 participants; adequate for Phase 2 surrogate endpoint detection.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07033494). This is a study registration, not published results. Lead sponsor: Merck Sharp & Dohme LLC. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 340 participants (ESTIMATED). Conditions: Early Alzheimer's Disease. Interventions: BIOLOGICAL: MK-2214; DRUG: Placebo. Primary outcome measures: Change from Baseline in Tau PET Standardized Uptake Value Ratio (SUVr) , Baseline, up to approximately 23 months; Number of Participants Who Experience One or More Adverse Events (AEs) , Up to approximately 26 months; Number of Participants Who Discontinue Study Intervention Due to an AE , Up to approximately 23 months. Brief summary: Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD. The goals of the study are to learn: * If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. * About the safety of MK-2214 and if people tolerate it

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

NCT07033494Early Alzheimer's DiseaseMerck Sharp & DohmeMK-2214